Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
50.74
0.00 (0.00%)
At close: Jan 17, 2025, 4:00 PM
50.73
-0.01 (-0.02%)
After-hours: Jan 17, 2025, 4:26 PM EST
Sanofi Employees
Sanofi had 86,088 employees as of December 31, 2023. The number of employees decreased by 5,485 or -5.99% compared to the previous year.
Employees
86,088
Change (1Y)
-5,485
Growth (1Y)
-5.99%
Revenue / Employee
$627,636
Profits / Employee
$58,378
Market Cap
128.27B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 86,088 | -5,485 | -5.99% |
Dec 31, 2022 | 91,573 | -3,869 | -4.05% |
Dec 31, 2021 | 95,442 | -3,970 | -3.99% |
Dec 31, 2020 | 99,412 | -997 | -0.99% |
Dec 31, 2019 | 100,409 | -3,817 | -3.66% |
Dec 31, 2018 | 104,226 | -2,340 | -2.20% |
Dec 31, 2017 | 106,566 | -293 | -0.27% |
Dec 31, 2016 | 106,859 | -2,230 | -2.04% |
Dec 31, 2015 | 109,089 | 1,702 | 1.58% |
Dec 31, 2014 | 107,387 | -4,741 | -4.23% |
Dec 31, 2013 | 112,128 | 154 | 0.14% |
Dec 31, 2012 | 111,974 | -1,745 | -1.53% |
Dec 31, 2011 | 113,719 | 12,144 | 11.96% |
Dec 31, 2010 | 101,575 | -3,292 | -3.14% |
Dec 31, 2009 | 104,867 | 6,654 | 6.78% |
Dec 31, 2008 | 98,213 | -1,282 | -1.29% |
Dec 31, 2007 | 99,495 | -794 | -0.79% |
Dec 31, 2006 | 100,289 | 3,108 | 3.20% |
Dec 31, 2005 | 97,181 | 742 | 0.77% |
Dec 31, 2004 | 96,439 | 63,353 | 191.48% |
Dec 31, 2003 | 33,086 | 650 | 2.00% |
Dec 31, 2002 | 32,436 | 1,922 | 6.30% |
Dec 31, 2001 | 30,514 | 1,314 | 4.50% |
Dec 31, 2000 | 29,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
SNY News
- 1 day ago - Top 4 Immunology Stocks Poised For Growth In 2025 - Seeking Alpha
- 6 days ago - Sanofi (SYN) CEO Paul Hudson Hosts 43rd Annual J.P. Morgan Healthcare (Transcript) - Seeking Alpha
- 7 days ago - Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025 - Seeking Alpha
- 7 days ago - Scribe Therapeutics Achieves Milestone for In Vivo Program in Collaboration with Sanofi - Business Wire
- 7 days ago - Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma - GlobeNewsWire
- 10 days ago - Sanofi: Underappreciated Powerhouse Primed For Long-Term Growth (Rating Upgrade) - Seeking Alpha
- 11 days ago - Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma - GlobeNewsWire
- 13 days ago - Alloy Therapeutics Announces a Target Specific Collaboration and License Agreement for use of AntiClastic™ Antisense Platform with Sanofi - Business Wire